CAGNONI PABLO J — SEC insider filings

SEC reporting owner CIK 1205703. 31 insider filings on record with FilingPulse; latest filed 2026-11-18.

Transaction summary — filings shown

Covers all 31 filings on record, filed 2021-02-02 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
INCYTE CORP (INCY)President, Global Head of R&D23—12 legs · 132,636 sh · $14,719,51059
Rubius Therapeutics, Inc. (RUBY)Director4—3 legs · 22,418 sh · $48,09310
Fusion Pharmaceuticals Inc. (FUSN)Director4——8

Insider filings — CAGNONI PABLO J

FiledFormIssuerReported transactionsSource
2026-11-184INCYTE CORP (INCY)Option exercise (M): 455 @ $61.18 · Option exercise (M): 422 @ $61.76 · Option exercise (M): 926 @ $64.25 · Option exercise (M): 839 @ $71.93 · Sale (S): 877 @ $121.98 · Sale (S): 1,765 @ $120.46 · +4 moreEDGAR
2026-10-194INCYTE CORP (INCY)Option exercise (M): 839 @ $71.93 · Option exercise (M): 423 @ $61.76 · Option exercise (M): 455 @ $61.18 · Option exercise (M): 925 @ $64.25 · Sale (S): 2,642 @ $112.71 · Option exercise (M): 839 (derivative) @ $0 · +3 moreEDGAR
2026-09-174INCYTE CORP (INCY)Option exercise (M): 2,957 @ $61.76 · Option exercise (M): 4,551 @ $61.18 · Option exercise (M): 6,477 @ $64.25 · Option exercise (M): 9,233 @ $71.93 · Sale (S): 9,233 @ $120.50 · Sale (S): 13,985 @ $120.49 · +4 moreEDGAR
2026-08-204INCYTE CORP (INCY)Sale (S): 10,801 @ $125.56EDGAR
2026-08-144INCYTE CORP (INCY)Sale (S): 10,803 @ $120.04EDGAR
2026-08-074INCYTE CORP (INCY)Sale (S): 10,640 @ $122.69EDGAR
2026-08-044INCYTE CORP (INCY)Sale (S): 15,888 @ $119.70EDGAR
2026-07-204INCYTE CORP (INCY)Grant/award (A): 13,403 @ $0 · Grant/award (A): 33,508 (derivative) @ $0 · Grant/award (A): 57,861 (derivative) @ $0EDGAR
2026-07-164INCYTE CORP (INCY)Tax withholding (F): 17,969 @ $114.88 · Tax withholding (F): 4,950 @ $115.09EDGAR
2026-06-034INCYTE CORP (INCY)Tax withholding (F): 25,469 @ $95.59EDGAR
2026-05-204/AINCYTE CORP (INCY)Grant/award (A): 31,517 @ $0EDGAR
2026-04-214INCYTE CORP (INCY)Option exercise (M): 6,077 @ $64.25 · Option exercise (M): 12,590 @ $71.93 · Sale (S): 18,667 @ $96.50 · Option exercise (M): 6,077 (derivative) @ $0 · Option exercise (M): 12,590 (derivative) @ $0EDGAR
2026-04-174INCYTE CORP (INCY)Grant/award (A): 27,892 @ $0EDGAR
2026-03-194INCYTE CORP (INCY)Option exercise (M): 7,166 @ $61.18 · Option exercise (M): 11,501 @ $64.25 · Sale (S): 18,667 @ $94.24 · Option exercise (M): 7,166 (derivative) @ $0 · Option exercise (M): 11,501 (derivative) @ $0EDGAR
2026-02-234INCYTE CORP (INCY)Option exercise (M): 13,093 @ $61.76 · Option exercise (M): 5,575 @ $61.18 · Sale (S): 18,668 @ $100.91 · Option exercise (M): 13,093 (derivative) @ $0 · Option exercise (M): 5,575 (derivative) @ $0EDGAR
2026-01-214INCYTE CORP (INCY)Grant/award (A): 28,475 (derivative) @ $0EDGAR
2025-07-164INCYTE CORP (INCY)Tax withholding (F): 1,280 @ $69.98 · Tax withholding (F): 2,628 @ $68.25 · Grant/award (A): 17,538 @ $0 · Grant/award (A): 43,846 (derivative) @ $0 · Grant/award (A): 39,471 (derivative) @ $0EDGAR
2025-01-224INCYTE CORP (INCY)Grant/award (A): 40,289 (derivative) @ $0EDGAR
2024-07-174INCYTE CORP (INCY)Grant/award (A): 19,851 @ $0 · Tax withholding (F): 749 @ $64.25 · Grant/award (A): 44,411 (derivative) @ $0EDGAR
2024-06-044Fusion Pharmaceuticals Inc. (FUSN)Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 141,011 (derivative)EDGAR
2024-01-224INCYTE CORP (INCY)Grant/award (A): 21,843 (derivative) @ $0EDGAR
2023-07-184INCYTE CORP (INCY)Grant/award (A): 9,668 @ $0 · Grant/award (A): 20,275 (derivative) @ $0EDGAR
2023-06-214/AINCYTE CORP (INCY)Grant/award (A): 192,400 @ $0EDGAR
2023-06-144Fusion Pharmaceuticals Inc. (FUSN)Grant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-074INCYTE CORP (INCY)Grant/award (A): 179,613 @ $0EDGAR
2023-02-014Rubius Therapeutics, Inc. (RUBY)Sale (S): 8,448 @ $0.25EDGAR
2023-01-314Rubius Therapeutics, Inc. (RUBY)Option exercise (M): 21,250 · Option exercise (M): 25,000 · Sale (S): 7,240 @ $0.24 · Option exercise (M): 21,250 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2022-06-224Fusion Pharmaceuticals Inc. (FUSN)Grant/award (A): 17,000 (derivative) @ $0EDGAR
2022-02-014Rubius Therapeutics, Inc. (RUBY)Option exercise (M): 21,250 · Sale (S): 6,730 @ $6.57 · Option exercise (M): 21,250 (derivative) @ $0 · Grant/award (A): 365,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2021-06-074Fusion Pharmaceuticals Inc. (FUSN)Grant/award (A): 17,000 (derivative) @ $0EDGAR
2021-02-024Rubius Therapeutics, Inc. (RUBY)Grant/award (A): 375,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1205703 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs